Sales leadership touting empty promises. Selling send out test we can't get paid on. Sales cuts ahead.
touting the genetics launch when it is a send out test we can't get paid on shows once again a flash in the pan.
CG is grabbing at straws, he knows the opportunity in genetics is long gone with reimbursement in the toilet and payers denying PA to most OON labs. It sounds like a desperate move to take the focus off the dismal future of OVA 1.
ASPIRA WOMEN'S HEALTH INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) | MarketScreener Nicole better hurry up and get this steaming pile sold STAT
